Tokyo, Aug. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058560) titled 'Association between Aqueous Humor Components and Retinal Diseases' on Aug. 1.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - Hirosaki University
Condition:
Condition - Retinal disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Anti-VEGF injection is the treatment for some of Retinal disease(Age-related macula degeneration, Diabetic macular edema, and others).In this treatment, the anterior chamber paracentesis prevent patients from ocular hypertation.
Althogh aqueous humor is usually discarded, we collect it to perform component analysis, such as VEGF concentration, to assess the prognostic implications for various retinal diseases.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients requiring anti-VEGF treatment who have given informed consent to participate in the research.
Key exclusion criteria - Patients with contraindications to the anti-VEGF treatment or anterior chamber paracentesis.(for example, intraocular infection)
Target Size - 100
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2024 Year 07 Month 18 Day
Date of IRB - 2024 Year 07 Month 18 Day
Anticipated trial start date - 2024 Year 07 Month 18 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066794
Disclaimer: Curated by HT Syndication.
